These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Soluble expression of a strong thrombolytic pro-urokinase mutant in Escherichia coli. Lin J; Yang X; Deng R; Yu B; Lai H; Sun W; Wu W Protein Expr Purif; 2006 Jul; 48(1):69-73. PubMed ID: 16503165 [TBL] [Abstract][Full Text] [Related]
23. Cloning and expression of the cathepsin F-like cysteine protease gene in Escherichia coli and its characterization. Joo HS; Koo KB; Park KI; Bae SH; Yun JW; Chang CS; Choi JW J Microbiol; 2007 Apr; 45(2):158-67. PubMed ID: 17483802 [TBL] [Abstract][Full Text] [Related]
24. Production and characterization of a novel tissue-type plasminogen activator derivative in Escherichia coli. Saito Y; Ishii Y; Sasaki H; Hayashi M; Fujimura T; Imai Y; Nakamura S; Suzuki S; Notani J; Asada T Biotechnol Prog; 1994; 10(5):472-9. PubMed ID: 7765373 [TBL] [Abstract][Full Text] [Related]
26. Elimination of the Cys558-Cys566 bond in Lys78-plasminogen--effect on activation and fibrin interaction. Linde V; Nielsen LS; Foster DC; Petersen LC Eur J Biochem; 1998 Jan; 251(1-2):472-9. PubMed ID: 9492320 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator. de Munk GA; Groeneveld E; Rijken DC Thromb Haemost; 1993 Sep; 70(3):481-5. PubMed ID: 8259553 [TBL] [Abstract][Full Text] [Related]
28. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. Ploug M; Kjalke M; Rønne E; Weidle U; Høyer-Hansen G; Danø K J Biol Chem; 1993 Aug; 268(23):17539-46. PubMed ID: 8394346 [TBL] [Abstract][Full Text] [Related]
29. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045 [TBL] [Abstract][Full Text] [Related]
30. Secretory production of recombinant urokinase-type plasminogen activator-annexin V chimeras in Pichia pastoris. Okabayashi K; Tsujikawa M; Morita M; Einaga K; Tanaka K; Tanabe T; Yamanouchi K; Hirama M; Tait JF; Fujikawa K Gene; 1996 Oct; 177(1-2):69-76. PubMed ID: 8921847 [TBL] [Abstract][Full Text] [Related]
31. Role of individual cysteine residues and disulfide bonds in the structure and function of Aspergillus ribonucleolytic toxin restrictocin. Nayak SK; Rathore D; Batra JK Biochemistry; 1999 Aug; 38(31):10052-8. PubMed ID: 10433712 [TBL] [Abstract][Full Text] [Related]
32. Characterization of thrombin- and plasmin-resistant mutants of recombinant human single chain urokinase-type plasminogen activator. Eguchi Y; Sakata Y; Matsuda M; Osada H; Numao N; Ohmori M; Kondo K J Biochem; 1990 Jul; 108(1):72-9. PubMed ID: 2146258 [TBL] [Abstract][Full Text] [Related]
33. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
34. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946 [TBL] [Abstract][Full Text] [Related]
35. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. Sherman PM; Lawrence DA; Yang AY; Vandenberg ET; Paielli D; Olson ST; Shore JD; Ginsburg D J Biol Chem; 1992 Apr; 267(11):7588-95. PubMed ID: 1559996 [TBL] [Abstract][Full Text] [Related]
36. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A; Knockaert I; Declerck PJ Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525 [TBL] [Abstract][Full Text] [Related]
37. Disulfide bond formation during the folding of influenza virus hemagglutinin. Segal MS; Bye JM; Sambrook JF; Gething MJ J Cell Biol; 1992 Jul; 118(2):227-44. PubMed ID: 1321156 [TBL] [Abstract][Full Text] [Related]
38. Alignment of disulfide bonds of the extracellular domain of the interferon gamma receptor and investigation of their role in biological activity. Stüber D; Friedlein A; Fountoulakis M; Lahm HW; Garotta G Biochemistry; 1993 Mar; 32(9):2423-30. PubMed ID: 8443182 [TBL] [Abstract][Full Text] [Related]
39. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein. Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462 [TBL] [Abstract][Full Text] [Related]
40. Secretion of a variant of human single-chain urokinase-type plasminogen activator without an N-glycosylation site in the methylotrophic yeast, Pichia pastoris and characterization of the secreted product. Tsujikawa M; Okabayashi K; Morita M; Tanabe T Yeast; 1996 May; 12(6):541-53. PubMed ID: 8771709 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]